Csenge Advisory Group acquired a new stake in AbbVie Inc (NYSE:ABBV) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 30,554 shares of the company’s stock, valued at approximately $2,715,000. AbbVie accounts for 1.1% of Csenge Advisory Group’s portfolio, making the stock its 15th biggest holding.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Shelton Capital Management raised its stake in AbbVie by 1.4% during the first quarter. Shelton Capital Management now owns 107,388 shares of the company’s stock worth $6,997,000 after acquiring an additional 1,457 shares in the last quarter. Sterling Investment Advisors Ltd. increased its stake in shares of AbbVie by 1.4% in the first quarter. Sterling Investment Advisors Ltd. now owns 17,540 shares of the company’s stock valued at $1,143,000 after buying an additional 250 shares in the last quarter. Westover Capital Advisors LLC increased its stake in shares of AbbVie by 4.0% in the first quarter. Westover Capital Advisors LLC now owns 10,144 shares of the company’s stock valued at $661,000 after buying an additional 388 shares in the last quarter. Flagship Harbor Advisors LLC increased its stake in shares of AbbVie by 9.2% in the first quarter. Flagship Harbor Advisors LLC now owns 12,798 shares of the company’s stock valued at $831,000 after buying an additional 1,080 shares in the last quarter. Finally, Zions Bancorporation increased its stake in shares of AbbVie by 6.6% in the first quarter. Zions Bancorporation now owns 8,720 shares of the company’s stock valued at $569,000 after buying an additional 542 shares in the last quarter. 69.28% of the stock is owned by institutional investors.
A number of analysts have recently weighed in on ABBV shares. Societe Generale raised their target price on AbbVie in a research note on Tuesday, November 21st. SunTrust Banks lifted their price objective on AbbVie to $157.00 and gave the stock an “average” rating in a research report on Monday. BidaskClub lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price objective for the company in a research report on Tuesday, October 17th. Finally, Jefferies Group lifted their price objective on AbbVie from $107.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. AbbVie currently has a consensus rating of “Buy” and an average target price of $115.07.
AbbVie Inc (ABBV) traded down $3.66 during midday trading on Wednesday, reaching $112.22. The company’s stock had a trading volume of 15,744,809 shares, compared to its average volume of 5,490,000. The company has a market cap of $178,890.00, a PE ratio of 27.24, a price-to-earnings-growth ratio of 1.24 and a beta of 1.53. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie Inc has a 12-month low of $59.75 and a 12-month high of $125.86.
AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.04. The firm had revenue of $7.74 billion for the quarter, compared to analysts’ expectations of $7.53 billion. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.20 EPS. sell-side analysts forecast that AbbVie Inc will post 7.54 earnings per share for the current fiscal year.
In other news, EVP Michael Severino sold 25,633 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the sale, the executive vice president now directly owns 114,922 shares in the company, valued at approximately $10,881,964.18. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Timothy J. Richmond sold 87,040 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. Following the sale, the senior vice president now owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders have sold a total of 476,376 shares of company stock worth $45,580,873 in the last ninety days. Insiders own 0.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Csenge Advisory Group Buys New Stake in AbbVie Inc (ABBV)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/31/csenge-advisory-group-purchases-new-position-in-abbvie-inc-abbv.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.